Novo Nordisk A/s

Cytoki Pharma Aps

Ziylo Limited

Thomas Hoeg-Jensen

Peter Madsen

Patrick William Garibay

Ib Jonassen

Palle Jakobsen

Svend Havelund

Tina Moeller Tagmose

Janos Tibor Kodra

Tina Møller Tagmose

Thomas Boerglum Kjeldsen

Per Sauerberg

Thomas Kruse

Henning Thoegersen

Carsten Behrens

Jan Markussen

Frantisek Hubalek

Miroslav Havranek

Thomas Børglum Kjeldsen

Mikael Kofod-Hansen

Ulla Ribel-Madsen

Martin Werner Borchsenius Muenzel

János Tibor Kodra

Ivan Snajdr

Per Balschmidt

Henning Thøgersen

Preben H Olesen

Anthony Murray

Ingrid Pettersson

Per Vedso

Jane Spetzler

Helle Birk Olsen

Ulrich Sensfuss

Ivan Verner Diers

Michi Egel-Mitani

Christian Fledelius

Ladislav Droz

Hana Drusanova

Vojtech Balsanek

Milan Stengl

Zuzana Drobnakova

Rasmus Jørgensen

Kristian Sass-Ørum

Sebastian Beck Jørgensen

Michael Paolo Bastner Sandrini

Vladislav Kotek

Tine Glendorf

Jacob Sten Petersen

Jakob Ewald Rasmussen

Tine Nygaard Vinther

Soren Ostergaard

Anthony Davis

Lauge Schaffer

Dorte Xenia Gram

Anne Plum

Charlotte Harkjaer Fynbo

Andrew Michael Chapman

Alice Ravn Madsen

Jakob Ewald

Henning THØGERSEN

Jaanos Tibor Kodra

Signe Ridderberg

Hana VÁNOVÁ

Miroslav HAVRÁNEK

Charlotte Harkjær Fynbo

Thomas Berglum Kjeldsen

Martin Werner Borchsenius MÜNZEL

Mikael Kofoed Hansen

Vojtech BALSÁNEK

Zuzana DROBNÁKOVÁ

The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Therapeutic derivatives of interleukin-22

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

Glucose-sensitive albumin-binding derivatives

The present invention provides glucose sensitive insulin derivatives comprising a macrocycle, a glucose mimetic and human insulin or an analogue thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such glucose sensitive insulin derivatives, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes.

Glucose sensitive insulins and uses thereof

The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.

Insulins with polar recombinant extensions

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X&#x2014;R2, and wherein 'X' is a mono- to multiatomic linker and where Rand R, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1&#x2032;-X&#x2032;&#x2014;R2&#x2032;, in which either the moeities R1&#x2032; or R2&#x2032; or X&#x2032; carry a drug that is covalently attached to the diboron compound.

The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.

Insulin compositions and method of making a composition

Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.

Protease stabilized acylated insulin analogues

Novel acylated insulin analoges exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analoges contain B25H and A14E or A14H.

The present invention relates to insulin derivatives having a side chain attached either to the &#x3b1;-amino group of the N-terminal amino acid residue of the B chain or to the &#x3b5;-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.

Insulin derivatives

The present invention regards an insulin derivative comprising at least 2 albumin binding moieties, wherein said albumin binding moieties comprise fatty diacid substitutions and a method for preparing such an insulin derivative by acylation and/or reductive alkylation. The present invention also concern a pharmaceutical comprising such an insulin derivative.

Multi-substituted insulins

An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary.

Insulin analogues with an acyl and alkylene glycol moiety

Protease stabilized, acylated insulin analogues

Growing community of inventors

Klampenborg, Denmark

Thomas Hoeg-Jensen